Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 2/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 10/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.38 |
| ▸ | CDK9 | P50750 | 3/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MELK | Q14680 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17511930 | 1.00 | CLK1 (0.43) | CLK1CSNK1DCSNK1EDYRK1AHASPIN | |
| SCHEMBL18036 | 0.85 | KDM4E (0.36) | CLK1CSNK1DCSNK1EDYRK1AHASPIN | |
| SCHEMBL18990 | 0.85 | PRKCZ (0.37) | CLK1CSNK1DCSNK1EDYRK1AHASPIN | |
| SCHEMBL70257 | 0.80 | — | — | |
| SCHEMBL559813 | 0.80 | — | — | |
| SCHEMBL445516 | 0.80 | CLK1 (0.57) | CLK1CSNK1DCSNK1EDYRK1AHASPIN | |
| SCHEMBL4036768 | 0.80 | CLK1 (0.57) | CLK1CSNK1DCSNK1EDYRK1AHASPIN | |
| SCHEMBL13156496 | 0.78 | CLK1 (0.55) | CLK1CSNK1DCSNK1EDYRK1AHASPIN | |
| SCHEMBL13156497 | 0.78 | CLK1 (0.55) | CLK1CSNK1DCSNK1EDYRK1AHASPIN | |
| SCHEMBL13156508 | 0.78 | CLK1 (0.55) | CLK1CSNK1DCSNK1EDYRK1AHASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6111110-A | Synthesis of benzo[f]quinolinones | ELI LILLY AND COMPANY (US) | 2000-08-29 | — | — | US | claimed |
| EP-0969003-A2 | Process for the preparation of benzo[f]quinolinone derivatives and intermediates | ELI LILLY AND COMPANY (US) | 2000-01-05 | — | — | EP | claimed |
| EP-0839807-A1 | Synthesis of benzo(f)quinolinones | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | claimed |
| US-9780310-B2 | Heterocyclic compound for organic electroluminescent device and its application | TOSOH CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | TOSOH CORPORATION (JP) | 2016-02-25 | — | — | US | disclosed |
| EP-0703221-B1 | 5 alpha-reductase Inhibitors | LILLY CO ELI (US) | 2002-03-27 | — | — | EP | disclosed |
| EP-0969003-A3 | Process for the preparation of benzo[f]quinolinone derivatives and intermediates | ELI LILLY AND COMPANY (US) | 2001-01-10 | — | — | EP | disclosed |
| US-6150375-A | INHIBITORS OF BOTH OF THE HUMAN 5AR ISOZYMES; BENIGN PROSTATE HYPERPLASIA, MALE PATTERN BALDNESS, ACNE VULGARIS, SEBORRHEA, ANDROGENIC ALOPECIA, HIRSUTISM AND PROSTATE CANCER; BLOCKS THE CONVERSION OF TESTOSTERONE TO 5-ALPHA-DIHYDROTESTOSTERONE | ELI LILLY AND COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
| US-6111110-A | Synthesis of benzo[f]quinolinones | ELI LILLY AND COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0969003-A2 | Process for the preparation of benzo[f]quinolinone derivatives and intermediates | ELI LILLY AND COMPANY (US) | 2000-01-05 | — | — | EP | disclosed |
| EP-0969003-A2 | Process for the preparation of benzo[f]quinolinone derivatives and intermediates | ELI LILLY AND COMPANY (US) | 2000-01-05 | — | — | EP | disclosed |
| US-5635197-A | BENZO(F)QUINOLIN-3-ONES; ANTICARCINOGENIC AGENTS; BONE DISORDERS | ELI LILLY AND COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| US-5629007-A | USING BENZOQUINOLIN-3-ONE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1997-05-13 | — | — | US | disclosed |
| US-5622961-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5622962-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5578724-A | INHIBITORS OF 5-ALPHA-REDUCTASE | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0742010-A2 | Benzoquinolin-3-ones to inhibit bone loss | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0733365-A2 | Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5550134-A | ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| EP-0703221-A1 | 5 alpha-reductase Inhibitors | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | AOC2, AZI2, KCNH2 | CLK1 3695/4885CSNK1D 4540/4885CSNK1E 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.